Founded in 2015, Oricell Therapeutics aims to develop drugs with good efficacy and affordable prices to satisfy the globally unmet clinical needs through innovations and strives to become the world-leading developer of novel drugs for tumor immunotherapy.
Location: China
Employees: 51-200
Total raised: $225M
Founded date: 2015
Investors 1
| Date | Name | Website |
| 06.01.2024 | Qiming Ven... | qimingvc.c... |
Funding Rounds 3
| Date | Series | Amount | Investors |
| 12.04.2026 | Pre-IPO | $110M | - |
| 12.01.2026 | - | $70M | OrbiMed |
| 28.02.2023 | Series B | $45M | - |
Mentions in press and media 14
| Date | Title | Description |
| 08.06.2026 | OriCell's GPC3 CAR-T Receives NMPA Clearance for Confirmatory Phase II Trial in Late-Line Advanced Hepatocellular Carcinoma | SHANGHAI, June 8, 2026 /PRNewswire/ -- OriCell Therapeutics Holdings Limited ( The "Company" or "Oricell") , announced that its proprietary GPC3-targeted autologous CAR-T therapy, Ori-C101, has received clearance from Ch... |
| 01.06.2026 | ASCO 2026 | Oricell's GPC3 CAR-T Ori-C101 Hits 66.7% ORR in Late-Line HCC, Signaling Best-in-Class Potential | CHICAGO, June 1, 2026 /PRNewswire/ -- Oricell Therapeutics, a clinical-stage biotech company pioneering cancer immunotherapy, today announced that its lead asset, Ori-C101, a GPC3-targeted CAR-T therapy, achieved a 66.7% objective response ... |
| 31.05.2026 | - | Hepatocellular carcinoma (HCC) remains a critical global health challenge, particularly in China, which accounts for more than one-third of the world's over 800,000 annual deaths from the disease. While frontline treatments have evolved, o... |
| 12.04.2026 | Oricell Therapeutics: $110 Million Pre-IPO Financing To Advance Solid Tumor CAR-T Pipeline | Oricell Therapeutics Holdings Limited, a clinical-stage biotechnology company focused on cancer immunotherapies, announced the closing of a pre-IPO financing round exceeding $110 million to support global expansion and accelerate developmen... |
| 10.04.2026 | China’s Oricell raises $110M for carcinoma CAR-T plans ahead of IPO push | Oricell Therapeutics has now raised over $110 million in its final funding round before the Chinese CAR-T therapy biotech seeks to go public. The Shanghai-based company secured backing from the likes of E-Town Capital, Luxin Venture Capital... |
| 10.04.2026 | Oricell Therapeutics Raises $110 Million to Advance Global Cell Therapy Development | Global Expansion Gains Momentum Oricell has raised $110 million in a major pre-IPO round. The company said the raise will speed up its global growth. It stressed that the funds would support clinical work across core assets. It also said th... |
| 10.04.2026 | Oricell Therapeutics Closes $110 Million Pre-IPO Financing to Accelerate Global Development of Solid Tumor CAR-T Therapies | SHANGHAI, April 10, 2026 /PRNewswire/ -- Oricell Therapeutics Holdings Limited ("Oricell"), a global clinical-stage biotechnology company pioneering innovative cancer immunotherapies, today announced the cumulative closing of a pr... |
| 12.01.2026 | Qiming-backed biotech Oricell raises $70m Series C1 round | - |
| 05.06.2024 | Oricell Presented Long-term Follow-up Data of OriCAR-017 in RRMM at 2024 ASCO Annual Meeting, Highlighting the Sustained Efficacy of GPRC5D CAR-T Therapy | SHANGHAI and ROSELAND, N.J., June 5, 2024 /PRNewswire/ -- Oricell Therapeutics, a pioneering clinical-stage biopharmaceutical company, has presented the two-year long-term follow-up results of OriCAR-017, an open-label Phase I study evaluat... |
| 29.01.2024 | Oricell Announces FDA Clearance of IND Application for OriCAR-017, a novel GPRC5D Targeted CAR-T Cell Therapy Utilizing the Company's Proprietary Platform, for the Treatment of Relapsed/Refractory Mul... | SHANGHAI and ROSELAND, N.J., Jan. 29, 2024 /PRNewswire/ -- Oricell Therapeutics (Oricell), a clinical-stage biotechnology company, today announced that the U.S. Food and Drug Administration (FDA) has cleared the company's Investigational Ne... |
Show more